In today’s briefing:
- FSN E-Commerce (Nykaa) Lockup Expiry – US$2.5bn Unlock with a Very Scattered Shareholding
- Delhivery: Potential Index Inclusions Overshadowed by US$2.89bn Lock-Up Expiry
- Archean Chemical Industries IPO – Outstanding Growth but Keep an Eye on Leverage
- 2023 High Conviction Idea: Cipla (CIPLA IN)- Complex Generics and India Business to Drive Growth
- Adani Ports – Earnings Flash – H1 FY 2022-23 Results – Lucror Analytics
- Five-Star Business IPO – Thoughts on Valuation
FSN E-Commerce (Nykaa) Lockup Expiry – US$2.5bn Unlock with a Very Scattered Shareholding
- In Nov 2021, Nykaa raised around US$720m in its India IPO, via mostly selling secondary shares.
- Nykaa is a lifestyle focussed e-commerce platform and consumer brand offering a portfolio of beauty, personal care and fashion products, including its own branded products.
- In this note, we will talk about the upcoming lockup expiry.
Delhivery: Potential Index Inclusions Overshadowed by US$2.89bn Lock-Up Expiry
- Delhivery (DELHIVER IN) raised US$675m in its IPO and started trading on 24 May. The stock dropped below its IPO price a couple of weeks ago.
- Lock-Ups on pre-IPO investors expire on 20 November with 598m shares (US$2.89bn) becoming available for sale. Sell before then or hold off on buying.
- Delhivery (DELHIVER IN) is a potential inclusion to the MSCI Small Cap and FTSE All-World indices in the next month. Passive buying will be overshadowed by lock-up expiry.
Archean Chemical Industries IPO – Outstanding Growth but Keep an Eye on Leverage
- Archean Chemical Industries (0810406D IN) is looking to raise about US$176m in its India IPO.
- Archean Chemical Industries (ACI) is a specialty marine chemical manufacturer in India focused on producing and exporting bromine, industrial salt, and sulphate of potash to customers around the world.
- ACI has been growing on the back of increasing production capacity, sales volume and average selling prices in recent years. However, the firm had nearly defaulted previously.
2023 High Conviction Idea: Cipla (CIPLA IN)- Complex Generics and India Business to Drive Growth
- Cipla Ltd (CIPLA IN) is a strong play in Indian generic pharmaceutical industry, due to its niche and differentiated respiratory and peptide injectable portfolio, which has less competition.
- The company has launched couple of complex respiratory products in the US market, which has accelerated its revenue growth. Multiple high-value launches are also lined up for this year.
- Cipla’s India business is on a strong footing, led by core portfolio tailwind in prescription and trade generics businesses. Q2FY23 marked the sixth consecutive quarter of market beating growth.
Adani Ports – Earnings Flash – H1 FY 2022-23 Results – Lucror Analytics
Adani Ports and Special Economic Zone’s (APSEZ) H1/22-23 results were moderately strong. The company reported robust earnings growth and margin expansion, supported by organic growth in cargo volumes and improved pricing. Leverage improved, as the company applied positive FCF towards debt reduction. That said, we expect slightly negative FY 2022-23 FCF, owing to higher full-year capex and the Haifa port acquisition.
We note APSEZ’s continued aggressive growth ambitions, which would keep Net Debt/EBITDA at a moderate 3-4x. The company’s intention to bid for the Container Corporation of India (valued at a hefty USD 5.8 bn) may present an event risk, though the impact on leverage would ultimately hinge on APSEZ’s funding plans.
Five-Star Business IPO – Thoughts on Valuation
- Five Star Business Finance (0958461D IN) is looking to raise around US$250m in its upcoming India IPO.
- Five-Star Business is a non-banking financial company (NBFC-ND-SI) that provides secured business loans to micro-entrepreneurs and self-employed individuals.
- We have looked at various aspects of the deal in our previous note, in this note, we talk about valuations.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars